Correlation between tuberous sclerosis complex 2 and glycogen synthase kinase 3 beta levels, and outcomes of patients with hepatocellular carcinoma treated by hepatectomy
- PMID: 24119083
- DOI: 10.1111/hepr.12256
Correlation between tuberous sclerosis complex 2 and glycogen synthase kinase 3 beta levels, and outcomes of patients with hepatocellular carcinoma treated by hepatectomy
Abstract
Aim: Tuberous sclerosis complex 2 (TSC2), a tumor suppressor, may play an essential role in the regulation of cell growth and cell survival under energy stress conditions. In addition, TSC2 may act in concert with Wnt and energy signals by additional phosphorylation of glycogen synthase kinase 3β (GSK3β) to regulate cell growth. The expression levels and function of TSC2 and GSK3β in hepatocellular carcinoma (HCC) remain unclear.
Methods: The protein levels of TSC2 and GSK3β were measured by immunohistochemistry in normal liver (n = 20), HCC (n = 80) and pericancerous tissues (n = 80). The correlations between TSC2, and GSK3β levels, clinicopathological features and patient survival were also analyzed.
Results: The protein levels of TSC2 and GSK3β in HCC tissues were significantly lower than that in normal liver tissues and pericancerous tissues (P < 0.05). Decreased TSC2 and GSK3β expression was found to be significantly correlated with advanced clinicopathological characteristics and poor prognosis. The results also showed that TSC2 protein levels were associated with GSK3β expression in HCC specimens.
Conclusion: This is the first demonstration that the decreases in TSC2 and GSK3β levels may be associated with vascular invasion, histological grade and tumor-node-metastasis classification.
Keywords: expression; glycogen synthase kinase 3β; hepatectomy; hepatocellular carcinoma; prognosis; tuberous sclerosis complex 2.
© 2013 The Japan Society of Hepatology.
Similar articles
-
TSC2 Mutations Were Associated with the Early Recurrence of Patients with HCC Underwent Hepatectomy.Pharmgenomics Pers Med. 2021 Feb 16;14:269-278. doi: 10.2147/PGPM.S294307. eCollection 2021. Pharmgenomics Pers Med. 2021. PMID: 33623416 Free PMC article.
-
Long non-coding RNA miR143HG predicts good prognosis and inhibits tumor multiplication and metastasis by suppressing mitogen-activated protein kinase and Wnt signaling pathways in hepatocellular carcinoma.Hepatol Res. 2019 Aug;49(8):902-918. doi: 10.1111/hepr.13344. Epub 2019 May 30. Hepatol Res. 2019. PMID: 30945380
-
TSC2 regulates microRNA biogenesis via mTORC1 and GSK3β.Hum Mol Genet. 2018 May 1;27(9):1654-1663. doi: 10.1093/hmg/ddy073. Hum Mol Genet. 2018. PMID: 29509898 Free PMC article.
-
Pivotal roles of glycogen synthase-3 in hepatocellular carcinoma.Adv Biol Regul. 2017 Aug;65:59-76. doi: 10.1016/j.jbior.2017.06.002. Epub 2017 Jun 6. Adv Biol Regul. 2017. PMID: 28619606 Review.
-
Pleiotropic effects of methionine adenosyltransferases deregulation as determinants of liver cancer progression and prognosis.J Hepatol. 2013 Oct;59(4):830-41. doi: 10.1016/j.jhep.2013.04.031. Epub 2013 May 7. J Hepatol. 2013. PMID: 23665184 Review.
Cited by
-
CircLIFR suppresses hepatocellular carcinoma progression by sponging miR-624-5p and inactivating the GSK-3β/β-catenin signaling pathway.Cell Death Dis. 2022 May 17;13(5):464. doi: 10.1038/s41419-022-04887-6. Cell Death Dis. 2022. PMID: 35581180 Free PMC article.
-
TSC1/2 mutations-a unique type of mutation suitable for liver transplantation of Hepatocellular carcinoma.J Gastrointest Oncol. 2021 Jun;12(3):1074-1085. doi: 10.21037/jgo-20-378. J Gastrointest Oncol. 2021. PMID: 34295558 Free PMC article.
-
TSC2 Mutations Were Associated with the Early Recurrence of Patients with HCC Underwent Hepatectomy.Pharmgenomics Pers Med. 2021 Feb 16;14:269-278. doi: 10.2147/PGPM.S294307. eCollection 2021. Pharmgenomics Pers Med. 2021. PMID: 33623416 Free PMC article.
-
GSK3α: An Important Paralog in Neurodegenerative Disorders and Cancer.Biomolecules. 2020 Dec 16;10(12):1683. doi: 10.3390/biom10121683. Biomolecules. 2020. PMID: 33339170 Free PMC article. Review.
-
Phosphoinositide 3-kinase inhibitors are effective therapeutic drugs for the treatment of hepatocellular carcinoma?Clin Mol Hepatol. 2020 Oct;26(4):577-578. doi: 10.3350/cmh.2020.0143. Epub 2020 Sep 17. Clin Mol Hepatol. 2020. PMID: 32937686 Free PMC article. No abstract available.
LinkOut - more resources
Full Text Sources
Other Literature Sources